We obviously, rolled out Zepbound and this is -- we're just now ... the patients lose weight, does it convert to long-term health benefit? The answer now, yes. Those are in submission review ...
Four GLP-1 receptor agonists have been approved for obesity treatment: Novo Nordisk’s Wegovy and Saxenda, Eli Lilly’s Zepbound ... the devices required to convert these into products ...
a ‘GLP-1’ that could rival the likes of Wegovy from Novo Nordisk and Eli Lilly’s Zepbound, could be published over the next year. Berenberg said its analysis of the returns Astra makes on its research ...
Biopharma executives shared their thoughts on the potential impacts of the new administration; Annalee Armstrong recaps JPM ...
A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...
The analysts expect launches of medicines including Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy to help add $20 billion to the value of the market in a decade. After a fallow period ...
For one, Lilly in early December shared the results of a head-to-head trial pitting Zepbound against Wegovy, in which Zepbound emerged triumphant. According to the study, participants taking ...
More than 69.2 million FDA-approved weight-loss prescriptions were dispensed in the U.S. from July 2017 through February 2024 ...
1 The research firm reached its conclusion based on a recent study that suggests that Zepbound may be more effective at promoting weight loss than Wegovy. The findings also took into consideration ...
BioWorld recorded 212 clinical trial updates, an increase from 180 in November and closely aligning with 219 in October. The month saw 16 successful phase III outcomes, along with two mixed results ...